share_log

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP:信函
美股SEC公告 ·  05/07 13:03

Moomoo AI 已提取核心信息

Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Mangoceuticals公司已正式向美国证券交易所(SEC)提出请求,加速Form S-1注册申请书的生效。初次文件提交于2024年4月23日,并已进行修改。总部位于德克萨斯州达拉斯的公司旨在使注册于2024年5月9日美东时间下午4:30生效。该请求是通过一封致Juan Grana的信件向SEC传达的,该信件指定为公司法律事务部主管,由Mangoceuticals的董事长兼首席执行官Jacob D. Cohen签署。
Mangoceuticals公司已正式向美国证券交易所(SEC)提出请求,加速Form S-1注册申请书的生效。初次文件提交于2024年4月23日,并已进行修改。总部位于德克萨斯州达拉斯的公司旨在使注册于2024年5月9日美东时间下午4:30生效。该请求是通过一封致Juan Grana的信件向SEC传达的,该信件指定为公司法律事务部主管,由Mangoceuticals的董事长兼首席执行官Jacob D. Cohen签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息